Gilead Sciences, Inc. (NASDAQ:GILD) Shares Sold by Ascent Group LLC

Ascent Group LLC decreased its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 8.6% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 15,142 shares of the biopharmaceutical company’s stock after selling 1,421 shares during the quarter. Ascent Group LLC’s holdings in Gilead Sciences were worth $1,109,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of GILD. Private Wealth Management Group LLC purchased a new position in shares of Gilead Sciences in the 4th quarter valued at $29,000. Sachetta LLC purchased a new position in Gilead Sciences in the fourth quarter valued at about $30,000. Palisade Asset Management LLC acquired a new position in shares of Gilead Sciences during the first quarter worth about $29,000. Rakuten Securities Inc. purchased a new stake in shares of Gilead Sciences in the fourth quarter worth about $33,000. Finally, Gladius Capital Management LP acquired a new stake in shares of Gilead Sciences in the fourth quarter valued at about $34,000. Institutional investors and hedge funds own 83.67% of the company’s stock.

Gilead Sciences Stock Performance

GILD stock traded down $0.26 during mid-day trading on Tuesday, reaching $77.47. The company had a trading volume of 1,376,633 shares, compared to its average volume of 7,404,110. Gilead Sciences, Inc. has a one year low of $62.07 and a one year high of $87.86. The stock has a market capitalization of $96.52 billion, a P/E ratio of 215.92, a P/E/G ratio of 3.28 and a beta of 0.18. The company has a quick ratio of 0.94, a current ratio of 1.08 and a debt-to-equity ratio of 1.31. The stock’s 50-day simple moving average is $67.99 and its two-hundred day simple moving average is $70.93.

Insider Buying and Selling

In other Gilead Sciences news, insider Merdad Parsey sold 2,000 shares of the business’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $68.63, for a total transaction of $137,260.00. Following the completion of the transaction, the insider now directly owns 96,380 shares of the company’s stock, valued at approximately $6,614,559.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

GILD has been the subject of a number of research analyst reports. Oppenheimer restated an “outperform” rating and issued a $105.00 price target on shares of Gilead Sciences in a research note on Friday, April 19th. Barclays cut their target price on shares of Gilead Sciences from $80.00 to $76.00 and set an “equal weight” rating on the stock in a research note on Monday, April 29th. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research note on Friday, April 26th. Morgan Stanley lowered their price objective on Gilead Sciences from $80.00 to $78.00 and set an “equal weight” rating for the company in a report on Friday, April 26th. Finally, TD Cowen reduced their target price on Gilead Sciences from $90.00 to $85.00 and set a “buy” rating on the stock in a report on Friday, April 26th. Twelve investment analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Gilead Sciences has a consensus rating of “Hold” and an average target price of $81.81.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.